Glofitamab for Follicular Lymphoma

Follicular lymphoma (FL) is the second most common subtype of non-Hodgkin lymphoma, characterized by the abnormal production of mature B-cells. While initial responses to standard chemotherapy and immunotherapy are typically strong, follicular lymphoma often returns (relapse) or becomes resistant to treatment (refractory). Over time, the side effects from standard therapies limit the options, especially in older patients and people  with chronic conditions. 

Glofitamab, a New Immunotherapy For Follicular Lymphoma

More clinical trials and treatment options are being developed to achieve better responses and longer periods of remission. Recently, immunotherapies have emerged as promising options for follicular lymphoma. They help the immune system find and destroy cancer cells while having fewer side effects. 

Glofitamab (Columvi) is a new bispecific antibody administered intravenously designed to attach to T-cells that eliminate lymphoma cells, helping relapsed or refractory follicular lymphoma patients. Its unique structure binds to two CD20 molecules on lymphoma cells and one CD3 molecule on T-cells, enhancing the immune response against lymphoma cells. It is currently approved for diffuse large B-cell lymphoma and large B-cell lymphoma derived from follicular lymphoma. It is currently featured in several clinical trials seeking its use for more non-Hodgkin lymphoma types including follicular lymphoma. 

Glofitamab in Follicular Lymphoma: Clinical Trial Highlights

Initial results for relapsed/refractory B-cell non-Hodgkin lymphoma 

This trial included a total of 171 patients, 44 of them with follicular lymphoma, who were treated with glofitamab following a single dose of obinutuzumab. Initial results showed a 70.5% overall response rate (ORR), including 47.7% of patients who achieved a complete response (CR). The most common side effects were cytokine release syndrome (CRS), fever, and neutropenia. This study is still ongoing and testing other innovative combinations with glofitamab - Check out the participating centers and see if it could be a good fit for you with our Clinical Trial Finder. 

Glofitamab in Combination with Polatuzumab Vedotin

A phase II study evaluated glofitamab monotherapy in patients with relapsed or refractory lymphoma who had received at least two prior treatments. Among 154 treated patients, the complete response (CR) rate was 40%, and the overall response rate (ORR) was 52%. After a median follow-up of 37.7 months, the median duration of CR was 29.8 months, with 57% of CR patients remaining progression-free and 77% alive two years after treatment. Biomarker analysis showed a rapid and sustained decrease in circulating tumor DNA (ctDNA) levels in responders, and immune system recovery, including B-cell and immunoglobulin restoration, began around 18 months post-treatment. The safety profile remained consistent with previous findings, with no new severe cytokine release syndrome or fatal adverse events. These results highlight the long-lasting remission potential and immune recovery benefits of fixed-duration glofitamab.

Glofitamab with Englumafusp Alfa trial NCT04077723 

Glofitamab is also being studied in combination with englumafusp alfa, an agent that targets CD19 and the receptor 4-1BB on T-cells. This combination showed promising results in a phase 1 trial, with an ORR of 91% and a CR rate of 73% in patients with relapsed/refractory follicular lymphoma.

Glofitamab in combination with bispecific antibody RO7443904 trial 

This trial tested the combination of glofitamab with a bispecific antibody that targets CD19 and repels CD28 named RO7443904, to enhance T-cell activity and potentially increase treatment efficacy for aggressive lymphomas.

Combination of Glofitamab with CELMoDs 

Combining Glofitamab with CELMoDs  is a phase 1 trial still recruiting. CELMoDs are small molecule agents designed to enhance immune activity and improve anti-cancer cells.  

Final Thoughts 

Glofitamab represents an exciting advancement for relapsed and refractory follicular lymphoma patients, offering more options for those who have tried multiple treatments. Its ability to engage T-cells to target and destroy cancerous B-cells has shown optimistic results in clinical trials, with high response and complete remission rates when combined with other therapies. As research continues, glofitamab and similar bispecific antibodies have the potential to extend remission periods and improve the quality of life for patients while reducing the side effects often seen with conventional treatments.

Keep learning more clinical trial updates with the HealthTree News site! 

Here, you can find all articles from different categories, from clinical trials, conferences, patient stories and more! 

KEEP READING MORE NEWS

Sources: 

• Targeted Therapy in Follicular Lymphoma: Towards a Chemotherapy-Free Approach
• The landscape of T-cell engagers for the treatment of follicular lymphoma
• Glofitamab Monotherapy in Relapsed or Refractory Large B-Cell Lymphoma: Extended Follow-Up from a Pivotal Phase II Study and Subgroup Analyses in Patients with Prior Chimeric Antigen Receptor T-Cell Therapy and by Baseline Total Metabolic Tumor Volume
•